title: High-resolution solution structure of the EGF-like domain of heregulin-alpha.
abstract: The solution structure of the 63-residue heregulin-alpha (HRG-alpha) epidermal growth factor (EGF)-like domain, corresponding to residues 177-239 of HRG-alpha, has been determined to high resolution using data from two-dimensional and three-dimensional homo- and heteronuclear NMR spectroscopy. The structure is based on a total of 887 internuclear distance and dihedral restraints derived from data obtained using unlabeled and uniformly 15N-labeled protein samples, at pH 4.5, 20 degrees C. A total of 20 structures were calculated using a hybrid distance geometry-simulated annealing approach with the program DGII, followed by restrained molecular dynamics using the program DISCOVER. The average maximum violations are 0.12 +/- 0.01 angstroms and 1.4 +/- 0.3 degrees for distance and dihedral restraints, respectively. The backbone (N,C(alpha),C) atomic rms distribution about the mean coordinates for residues 3-23 and 31-49 is 0.29 +/- 0/07 angstroms. The N-and C-terminal residues (1-2 and 50-63) and 24-30 are disordered. Comparison of the HRG-alpha EGF-like domain structure with the previously determined structure of human EGF [Hommel et al. (1992) J. Mol. Biol. 227, 271-282] reveals a high degree of structural similarity; excluding the N-terminal region (residues 1-13), the disordered phi-loop region (residues 24-30) that contains a three-residue insertion in HRG-alpha relative to hEGF, and the disordered C-terminal region (residues 50-63), the C(alpha) alignment between the HRG-alpha and hEGF minimized mean structures has a rms difference of approximately 1 angstrom. In HRG-alpha the N-terminal residues 2-6 form a well-defined beta strand rather than being disordered as found for hEGF. This structural difference correlates with functional data which suggest that the N-terminal region of the HRG-alpha EGF-like domain is responsible for the observed receptor specificity differences between HRG-alpha and EGF.
authors.affiliation: Department of Protein Engineering, Genentech, Inc., South San Francisco, California 94080, USA.
authors.forename: N E
authors.initials: NE
authors.lastname: Jacobsen
authors.forename: N
authors.initials: N
authors.lastname: Abadi
authors.forename: M X
authors.initials: MX
authors.lastname: Sliwkowski
authors.forename: D
authors.initials: D
authors.lastname: Reilly
authors.forename: N J
authors.initials: NJ
authors.lastname: Skelton
authors.forename: W J
authors.initials: WJ
authors.lastname: Fairbrother
mesh_terms: D000595:Amino Acid Sequence; D004220:Disulfides / Q000737:chemistry; D006023:Glycoproteins / Q000737:chemistry*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D008969:Molecular Sequence Data; D020880:Neuregulins; D010455:Peptides / Q000737:chemistry; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins; D016415:Sequence Alignment; D012996:Solutions
chemical_list: D004220:Disulfides; D006023:Glycoproteins; D020880:Neuregulins; D010455:Peptides; D011994:Recombinant Proteins; D012996:Solutions